Burden of In-Clinic and At-Home Administration of Injectable Biologics for Severe Asthma and Chronic Rhinosinusitis With Nasal Polyps: Interim Results From a Time and Motion Study
Author(s)
Erwin De Cock, MSc1, Jacquelyne Brauneis, MPH2, Julie Prock, MPH3, waseem ahmed, MBA4, Saeed Noibi, MPH5, Rafael Alfonso-Cristancho, MD, PhD6.
1Real World and Late Phase, Syneos Health, Barcelona, Spain, 2Real World and Late Phase, Syneos Health, Morrisville, NC, USA, 3Insights and Evidence Generation, Syneos Health, Morrisville, NC, USA, 4Global Real World Evidence and Health Outcomes, GSK, London, United Kingdom, 5Global Real World Evidence and Health Outcomes, GSK, Jeddah, Saudi Arabia, 6Global Real World Evidence and Health Outcomes, GSK, Collegeville, PA, USA.
1Real World and Late Phase, Syneos Health, Barcelona, Spain, 2Real World and Late Phase, Syneos Health, Morrisville, NC, USA, 3Insights and Evidence Generation, Syneos Health, Morrisville, NC, USA, 4Global Real World Evidence and Health Outcomes, GSK, London, United Kingdom, 5Global Real World Evidence and Health Outcomes, GSK, Jeddah, Saudi Arabia, 6Global Real World Evidence and Health Outcomes, GSK, Collegeville, PA, USA.
OBJECTIVES: Quantify healthcare professional (HCP) and patient time associated with in-clinic and at-home injectable biologic administration for severe asthma (SA) and/or chronic rhinosinusitis with nasal polyps (CRSwNP).
METHODS: This multi-country study focused on HCPs performing pre-specified management/administration tasks related to injectable biologics of adult patients with SA, CRSwNP, or comorbid SA with CRSwNP in 15 sites (8 countries). Interim results from China (2 sites), France (1), Japan (2), and the United Kingdom (UK; 2) are reported. Active HCP time was measured via stopwatch (sequential tasks) and time-of-day self-observation/estimates via interview (non-sequential tasks). Patient time was collected as time-of-day (in-clinic) and elicited via surveys (in-clinic and at-home). Target samples were up to 20 observations per site (in-clinic administration; excluding France) and up to 10 observations per task (at-home administration). A time model included biologic administration frequency for dupilumab (every 2 weeks [Q2W]), mepolizumab (Q4W), omalizumab (Q4W), tezepelumab (Q4W), and benralizumab (Q8W). Pooled country results were modelled for the first year of treatment.
RESULTS: In addition to data collected at sites, patient surveys were collected in China (n=39), Japan (n=56), France (n=15), and the UK (n=69). Both in-clinic and at-home biologic administration, respectively, were associated with considerable HCP time burden (range across biologics, yearly hours): 2.60−7.78 and 2.08−3.37 (China); 2.51−4.28 and 2.32−2.32 (Japan); 3.17−7.67 and 1.46−1.49 (France); 5.90−17.75 and 3.44−3.44 (UK). Considerable patient time burden was associated with both in-clinic and at-home administration, respectively (yearly hours): 34.5−110.3 and 24.1−53.9 (China); 38.1−83.5 and 19.6−22.1 (Japan); 14.3−38.9 and 7.3−10.6 (France); 23.1−71.7 and 11.1−11.1 (UK). For all ranges, dupilumab and benralizumab were associated with the greatest and smallest time burden, respectively.
CONCLUSIONS: Both in-clinic and at-home injectable biologic administration were associated with considerable HCP and patient time, with higher dosing frequency driving greater burden. Heterogeneity was observed between countries, likely driven by healthcare system differences.
Funding: GSK (214575).
METHODS: This multi-country study focused on HCPs performing pre-specified management/administration tasks related to injectable biologics of adult patients with SA, CRSwNP, or comorbid SA with CRSwNP in 15 sites (8 countries). Interim results from China (2 sites), France (1), Japan (2), and the United Kingdom (UK; 2) are reported. Active HCP time was measured via stopwatch (sequential tasks) and time-of-day self-observation/estimates via interview (non-sequential tasks). Patient time was collected as time-of-day (in-clinic) and elicited via surveys (in-clinic and at-home). Target samples were up to 20 observations per site (in-clinic administration; excluding France) and up to 10 observations per task (at-home administration). A time model included biologic administration frequency for dupilumab (every 2 weeks [Q2W]), mepolizumab (Q4W), omalizumab (Q4W), tezepelumab (Q4W), and benralizumab (Q8W). Pooled country results were modelled for the first year of treatment.
RESULTS: In addition to data collected at sites, patient surveys were collected in China (n=39), Japan (n=56), France (n=15), and the UK (n=69). Both in-clinic and at-home biologic administration, respectively, were associated with considerable HCP time burden (range across biologics, yearly hours): 2.60−7.78 and 2.08−3.37 (China); 2.51−4.28 and 2.32−2.32 (Japan); 3.17−7.67 and 1.46−1.49 (France); 5.90−17.75 and 3.44−3.44 (UK). Considerable patient time burden was associated with both in-clinic and at-home administration, respectively (yearly hours): 34.5−110.3 and 24.1−53.9 (China); 38.1−83.5 and 19.6−22.1 (Japan); 14.3−38.9 and 7.3−10.6 (France); 23.1−71.7 and 11.1−11.1 (UK). For all ranges, dupilumab and benralizumab were associated with the greatest and smallest time burden, respectively.
CONCLUSIONS: Both in-clinic and at-home injectable biologic administration were associated with considerable HCP and patient time, with higher dosing frequency driving greater burden. Heterogeneity was observed between countries, likely driven by healthcare system differences.
Funding: GSK (214575).
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD18
Topic
Health Service Delivery & Process of Care
Disease
Biologics & Biosimilars, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)